Abstract
Inflammation plays a role at all stages of atherosclerosis. Neopterin, a pteridine mainly synthesized by activated macrophages, is a marker of inflammation, immune system activation and an active participant in cardiovascular disease. Measurement of neopterin levels may help follow the evolution of specific inflammatory conditions (e.g. viral infection, renal transplant rejection, systemic inflammatory diseases, nephritic syndrome and autoimmune diseases). Serum levels of neopterin are elevated also in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Moreover, plasma levels of this molecule might predict adverse cardiovascular events in patients with CAD, acute coronary syndromes or severe PAD. In addition, neopterin levels are related to the development of heart failure. We provide an updated overview on neopterin and, its links with CAD, left ventricular dysfunction, and PAD. We also describe its potential role in cardiac regenerative strategies with using bone marrow cells.
Keywords: Atherosclerosis, cardiovascular disease, inflammation, neopterin
Current Vascular Pharmacology
Title: Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Volume: 9 Issue: 2
Author(s): Salvatore De Rosa, Plinio Cirillo, Mario Pacileo, Gianluca Petrillo, Greta-Luana D'Ascoli, Fabio Maresca, Francesca Ziviello and Massimo Chiariello
Affiliation:
Keywords: Atherosclerosis, cardiovascular disease, inflammation, neopterin
Abstract: Inflammation plays a role at all stages of atherosclerosis. Neopterin, a pteridine mainly synthesized by activated macrophages, is a marker of inflammation, immune system activation and an active participant in cardiovascular disease. Measurement of neopterin levels may help follow the evolution of specific inflammatory conditions (e.g. viral infection, renal transplant rejection, systemic inflammatory diseases, nephritic syndrome and autoimmune diseases). Serum levels of neopterin are elevated also in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Moreover, plasma levels of this molecule might predict adverse cardiovascular events in patients with CAD, acute coronary syndromes or severe PAD. In addition, neopterin levels are related to the development of heart failure. We provide an updated overview on neopterin and, its links with CAD, left ventricular dysfunction, and PAD. We also describe its potential role in cardiac regenerative strategies with using bone marrow cells.
Export Options
About this article
Cite this article as:
De Rosa Salvatore, Cirillo Plinio, Pacileo Mario, Petrillo Gianluca, D'Ascoli Greta-Luana, Maresca Fabio, Ziviello Francesca and Chiariello Massimo, Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519372
DOI https://dx.doi.org/10.2174/157016111794519372 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drugs in Newborn Resuscitation: The More We Learn the Least We Use
Current Medicinal Chemistry Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Postoperative Thoracic Epidural Anesthesia in Gastrointestinal Surgery: Outcomes, Quality of Life, and Current Controversies
Current Drug Therapy Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus
Current Cardiology Reviews The Potential Application of Biomaterials in Cardiac Stem Cell Therapy
Current Medicinal Chemistry Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Vasculopathy in Hyperthyroid Rats and Targets for Drug Effects
Vascular Disease Prevention (Discontinued) On the Role of Endothelial TRPC3 Channels in Endothelial Dysfunction and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Highest Mortality During the Last Year Before and the First Year After Start of Dialysis Treatment in Type 2 Diabetic Patients with Nephropathy
Current Diabetes Reviews Microvascular Thrombosis: An Exciting but Elusive Therapeutic Target in Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?
Current Pharmaceutical Design Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design